The goal of this PPG is to explore one of the major unsolved problems of modern tumor immunology, namely, the fate of immune cells in the tumor microenvironment. The working hypothesis is that in the patients with cancer, the immune cells are unable to effectively mediate anti-tumor activities, because human tumor cells can escape from the immune response and/or actively interfere with the differentiation, function and/or survival of immune effector cells. The failure of immunotherapy, including anti-tumor vaccines, to control tumor growth probably results from tumor-mediated dysfunction of the immune system and/or from successful strategies evolved by tumor cells to avoid immune detection. These hypotheses are solidly based on our preliminary data documenting dysfunction, Th2 deviation and spontaneous apoptosis of circulating CD8+ T cells;differentiation defects in dendritic cells (DC);and aberrations in the antigen processing machinery (APM) and antigen presentation by tumor cells. In four projects supported by four cores, this PPG will attempt to dissect mechanisms responsible for these abnormalities in anti-tumor immune responses. An improved understanding of these mechanisms is essential for the development of novel therapeutic strategies designed to protect tumor-specific effector T cells from apoptosis and restore balanced Th1/Th2 responses, adequate polarization and functions of DC as well as improved presentation of HLA-class l-tumor peptide complexes on the tumor cell surface. Cytokines and their impact on lymphocyte survival and tumor escape will be evaluated in vitro and in vivo, as part of the proposed clinical trials. In Project 1, spontaneous apoptosis of circulating tumor-specific CD8+ T cells will be investigated in patients with HNC or melanoma. Project 2 will explore molecular and functional consequences of immune deviation in tumor-antigen specific T helper cells in patients with renal cell cancer. In Project 3, new scFv probes for detection and quantitation of HLA-class I-tumor-peptide complexes will be developed and, together with antibodies to APM components, used for studies of mechanisms that contribute to tumor escape in patients with HNC. Clinical significance of APM defects and their repair upon therapy with IFN-y will be assessed. To accomplish these objectives, the PPG brings together basic and clinical investigators experienced in cancer immunology/immunotherapy. The overall goal is to prevent tumor cell escape and thereby improve effectiveness of anti-tumor immunotherapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA109688-04S1
Application #
7910336
Study Section
Special Emphasis Panel (ZCA1-GRB-2 (J))
Program Officer
Timmer, William C
Project Start
2009-08-01
Project End
2011-07-31
Budget Start
2009-08-01
Budget End
2011-07-31
Support Year
4
Fiscal Year
2009
Total Cost
$303,000
Indirect Cost
Name
University of Pittsburgh
Department
Pathology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Spitler, Lynn E; Cao, Huynh; Piironen, Timo et al. (2017) Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma. Am J Clin Oncol 40:207-213
Macatangay, Bernard J C; Riddler, Sharon A; Wheeler, Nicole D et al. (2016) Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis 213:1400-9
Szczepanski, Miroslaw J; Luczak, Michal; Olszewska, Ewa et al. (2015) Molecular signaling of the HMGB1/RAGE axis contributes to cholesteatoma pathogenesis. J Mol Med (Berl) 93:305-14
Whiteside, Theresa L (2015) Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV. Cancer Microenviron 8:201-7
Schuler, P J; Saze, Z; Hong, C-S et al. (2014) Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol 177:531-43
Schuler, Patrick J; Harasymczuk, Malgorzata; Visus, Carmen et al. (2014) Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 20:2433-44
Whiteside, Theresa L (2014) Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 63:67-72
Schuler, Patrick J; Harasymczuk, Malgorzata; Schilling, Bastian et al. (2013) Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res 19:6585-96
Whiteside, Theresa L (2013) Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 41:245-51
Chi Sabins, Nina; Taylor, Jennifer L; Fabian, Kellsye P L et al. (2013) DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature. Mol Ther 21:1958-68

Showing the most recent 10 out of 110 publications